πŸ‡ΊπŸ‡Έ FDA
Patent

US 12247213

Treatment of mucopolysaccharidosis IVA

granted A61KA61K38/00A61K48/0058

Quick answer

US patent 12247213 (Treatment of mucopolysaccharidosis IVA) held by REGENXBIO INC. expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENXBIO INC.
Grant date
Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61K48/0058, A61P, A61P19/00